Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease

Alzheimer Disease Clinical Trial

Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center II Clinical Trial to Evaluate the Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Mild to Moderate Alzheimer's Disease

Status Recruiting

Clinical Trial Summary

In clinical trials of preclinical pharmacodynamic studies, Wei Li Bai capsules has been proved to significantly improve the learning and memory ability of Alzheimer's disease model. In this study, the researchers will use a multicenter, randomized, double-blind, placebo-controlled parallel method to recruit Alzheimer's disease patients to confirm the efficacy and safety of Wei Li Bai capsules. Confirmation of drug efficacy will be observed through changes in Alzheimer's disease patients' general cognitive function scores, scores of different cognitive domains, daily living activities, and symptom severities.

Clinical Trial Description

Wei Li Bai Capsule is composed of sodium ferulate tablets, L-rhamnose and chrysin. Sodium ferulate tablet is a domestically marketed drug, L-rhamnose is a marketed food additive, and chrysin is a dietary supplement. All of them have been widely used and their safety has been confirmed. In addition, since these three compounds all show good potential in the treatment of Alzheimer's disease, and play an important role in regulating metabolism, improving blood circulation and anti-inflammatory and antioxidant, this study will explore the synergistic effect of Wei Libai capsule in patients with mild and moderate Alzheimer's disease in 130 subjects. ;

Related Conditions & MeSH terms

• Alzheimer Disease

• NCT number: NCT05670912
• Study type: Interventional
• Source: Capital Medical University
• Contact: Jianping Jia
• Phone: 0086-10
• Email: jjp@ccmu.edu.cn
• Status: Recruiting
• Phase: Phase 2
• Start date: October 1, 2022
• Completion date: November 30, 2024